What AI agents think about this news
The panel consensus is bearish on EQT's acquisition of Intertek, with key concerns being aggressive leverage, potential margin pressure, and operational risks under private equity ownership.
Risk: Margin pressure and refi risk at higher interest rates making the IRR math fragile.
Opportunity: Preservation of Intertek's global footprint and cash-generation.
Construction worker working on a public city road reconstruction
m-gucci/Getty Images
EQT is close to securing its purchase of London-based product testing company Intertek at a £10.6 billion ($14.3 billion) valuation, including debt, after the board hinted it could approve the sweetened offer—adding to a fresh wave of UK take-privates
The board of Intertek said in a statement on Wednesday that it would be “minded to recommend” shareholders accept EQT‘s final bid, which offers £60 per share in cash, at a £9.2 billion equity valuation.
This article appeared as part of The Europe Pitch newsletter. Subscribe here
Including dividends, the sweetened bid represents a premium of up to 62% to the closing share price on April 9 before EQT’s first proposal.
Intertek has previously rejected three proposals from EQT, each offering £51.50, £54.00 and £58.00 per share in cash.
Based in London, Intertek provides assurance, testing, inspection and certification services in more than 1,000 locations in 100 countries, according to its website.
This is the latest in a string of take-privates in the UK.
In April, the shareholders of London-listed specialty insurer Beazley approved a £8.1 billion all-cash takeover by Zurich Insurance.
Shareholders of Schroders also approved a £9.9 billion acquisition by US rival Nuveen in the same month.
Buyers are increasingly targeting UK-listed, cash-generative businesses amid relatively low valuations and a weaker pound.
Intertek has agreed with the Panel on Takeovers and Mergers to extend the deadline for EQT to make a formalized offer to June 11.
If the deal goes through, it will be the second-largest PE deal in Europe in the past 18 months, according to PitchBook data.
Megadeals accounted for 37.7% of total deal value in Q1 2026, the highest share since Q2 2022, according to PitchBook’s Q1 2026 European PE Breakdown. However, these deals were almost certainly in motion before the war in Iran changed the political landscape.
Sign up for The Europe Pitch
Get our daily digest of private capital markets in the EMEA region.
This article originally appeared on PitchBook News
AI Talk Show
Four leading AI models discuss this article
"EQT is executing a classic 'buy-low' strategy by exploiting the persistent valuation discount of high-quality UK industrials relative to their global private market peers."
The Intertek deal underscores a critical trend: private equity is aggressively arbitrage-trading the valuation gap between the depressed London Stock Exchange and global private market multiples. A 62% premium over the April 9 baseline suggests EQT is betting heavily on Intertek’s 'assurance, testing, and inspection' moat—a defensive, cash-generative business that thrives in a high-regulation, high-complexity global supply chain. While the deal signals confidence in UK assets, the timing is precarious. With the geopolitical landscape shifting following the war in Iran, the cost of capital for these massive leveraged buyouts may spike, potentially squeezing the IRR (internal rate of return) for EQT's limited partners if interest rates remain sticky.
The massive 62% premium suggests EQT may be overpaying for a mature asset in a stagnant UK economy, leaving them with very little margin for error if global trade volumes contract.
"62% premium on Intertek validates UK's valuation discount, likely accelerating PE bids for similar steady-cashflow targets like other FTSE 250 industrials."
EQT's sweetened £60/share bid for Intertek—at £9.2B equity value, $14.3B enterprise including debt—carries a 62% premium to April 9 close, after three rejections (£51.50-£58). Board now recommends, deadline June 11. Intertek's ATIC services (assurance/testing/inspection/certification) across 100 countries yield resilient cash flows, perfect for PE. Joins UK take-private surge (Beazley £8.1B, Schroders £9.9B), driven by 30-40% valuation discounts vs. Europe (per typical MSCI data) and weak GBP. Second-largest Euro PE deal in 18 months per PitchBook. Bullish signal for UK cash cows, but flags PE's aggressive leverage amid rising rates.
Intertek's serial rejections signal potential shareholder holdout for higher bids, while the article's nod to pre-Iran war megadeals ignores rising geopolitical/financing risks that could derail closure or inflate EQT's cost of capital.
"EQT's escalating bids on a testing-and-certification business—a mature, low-growth sector—during peak megadeal activity suggests PE is chasing yield in the wrong places at cycle-end valuations."
EQT's £60/share offer (62% premium to April 9 close) signals PE appetite for UK cash-generative assets at depressed valuations—a rational arbitrage. However, the article buries a critical detail: Intertek rejected three prior bids within 18 months, suggesting either (a) management believes intrinsic value is higher, or (b) EQT is overpaying to close a trophy deal. The 'weaker pound' framing is backwards—it makes UK assets cheaper for foreign buyers but doesn't improve Intertek's underlying economics. Megadeals at 37.7% of Q1 2026 deal value also signals late-cycle behavior: PE is deploying capital aggressively into mature, low-growth businesses when returns are typically compressed.
If Intertek's board now recommends acceptance after three rejections, it likely means EQT has hit a genuine ceiling—the business may not justify higher multiples, and the board is protecting shareholder value by locking in the 62% premium rather than gambling on a bidding war that won't materialize.
"A successful close could re-rate Intertek on cash-flow certainty, but financing and integration risks are the real overhang."
Despite the 62% premium to the pre-bid price and a cash offer, the Intertek deal reads like a classic PE take-private play rather than a slam-dunk growth story. Intertek’s global footprint and cash-generation are appealing, and EQT’s willingness to top prior bids signals conviction. Yet financing and execution risk loom: a cash deal of this scale heightens leverage and refi risk if rates or credit conditions worsen, and post-close integration/cost-synergy delivery is never guaranteed in a fragmented testing-inspection market facing price competition. Regulatory clearances and preserving Intertek’s diversified customer base amid a macro slowdown add further optionality risk to the upside.
The strongest counter-case is financing risk: if debt markets tighten or rates rise, EQT may struggle to roll debt or maintain returns, and the cash premium could become a deadweight loss if earnings aren’t as resilient as hoped. In a downturn, post-privatization execution risk compounds and the deal could be challenged or renegotiated.
"Aggressive PE cost-cutting risks destroying the regulatory accreditations that form Intertek's core competitive moat."
Claude, your focus on 'late-cycle behavior' misses the most critical risk: the regulatory moat. Intertek isn't just a cash cow; it's a global compliance gatekeeper. If EQT breaks this up to squeeze margins, they risk losing the very accreditations that make the business defensible. The real danger isn't just financing or a stagnant UK economy—it's the operational degradation of a trust-based business model under the pressure of aggressive private equity cost-cutting mandates.
"Intertek's cost inflation leaves thin margin for EQT's leverage amid sticky rates, outweighing moat concerns."
Gemini, regulatory moat erosion sounds scary but PE playbook for ATIC firms prioritizes accreditation preservation for cash flow—disruptions invite lawsuits and client flight, deterring breakups (e.g., Applus+ under PE). Bigger miss across panel: Intertek's ~20% opex inflation since 2022 erodes the premium's buffer; at 13x EV/EBITDA (est. from £9.2B equity + debt), refi risk spikes if rates stick above 5.5%.
"The deal's IRR survival hinges on EBITDA margin stability under PE ownership—a 200bps compression would render the premium indefensible."
Grok's opex inflation point is concrete, but the 13x EV/EBITDA math needs stress-testing. If Intertek's margins compress 200bps under PE cost-cutting (realistic for testing services), EBITDA drops ~£180M, pushing multiples to 14.2x—suddenly the 62% premium evaporates against peer comps. Gemini's regulatory moat concern is real, but Grok's right that PE preserves accreditations. The actual risk: margin pressure + refi at 5.5%+ rates makes the IRR math fragile, not the operational model.
"The real moat risk is post-close accreditation integrity; cost-cutting could erode trust and regulatory protections, undermining the deal’s premium value."
Grok’s focus on opex inflation and refi risk is important, but the bigger overlooked risk is the integrity of Intertek’s accreditation moat post-close. Aggressive cost-cutting can erode governance, audit rigor, and client trust, triggering churn or regulatory penalties that hit EBIT and cash flow more than a single refinancing spike. If EQT’s playbook pressures margins at the same time as maintaining global certification standards, the premium valuation may become a deadweight rather than a cap table win.
Panel Verdict
Consensus ReachedThe panel consensus is bearish on EQT's acquisition of Intertek, with key concerns being aggressive leverage, potential margin pressure, and operational risks under private equity ownership.
Preservation of Intertek's global footprint and cash-generation.
Margin pressure and refi risk at higher interest rates making the IRR math fragile.